Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: What are the optimal criteria?

J Hepatol. 2024 Apr;80(4):e171-e172. doi: 10.1016/j.jhep.2023.09.034. Epub 2023 Oct 10.

Authors

Meng Sha¹, Jie Cao², Qiang Xia³

Affiliations

¹ Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China. Electronic address: simonsha23@163.com.
² Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
³ Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China. Electronic address: xiaqiang@shsmu.edu.cn.

PMID: 37821020
DOI: 10.1016/j.jhep.2023.09.034

No abstract available

Publication types

Letter

MeSH terms

Biomarkers
Biomarkers, Tumor
Carcinoma, Hepatocellular* / pathology
Carcinoma, Hepatocellular* / surgery
Humans
Liver Neoplasms* / pathology
Liver Neoplasms* / surgery
Liver Transplantation*
Patient Selection
Prothrombin
alpha-Fetoproteins

Substances

alpha-Fetoproteins
Biomarkers, Tumor
Biomarkers
Prothrombin